- Home
- SBRA vs ICUI Comparison
SBRA vs ICUI Comparison
Compare SBRA & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- ICUI
- Stock Information
- Founded
- SBRA 2010
- ICUI 1984
- Country
- SBRA United States
- ICUI United States
- Employees
- SBRA N/A
- ICUI N/A
- Industry
- SBRA Real Estate Investment Trusts
- ICUI Medical/Dental Instruments
- Sector
- SBRA Real Estate
- ICUI Health Care
- Exchange
- SBRA Nasdaq
- ICUI Nasdaq
- Market Cap
- SBRA N/A
- ICUI 3.4B
- IPO Year
- SBRA N/A
- ICUI 1992
- Fundamental
- Price
- SBRA $18.47
- ICUI $133.44
- Analyst Decision
- SBRA Buy
- ICUI Strong Buy
- Analyst Count
- SBRA 7
- ICUI 5
- Target Price
- SBRA $19.71
- ICUI $196.75
- AVG Volume (30 Days)
- SBRA 2.5M
- ICUI 215.9K
- Earning Date
- SBRA 08-06-2025
- ICUI 08-06-2025
- Dividend Yield
- SBRA 6.50%
- ICUI N/A
- EPS Growth
- SBRA 185.79
- ICUI N/A
- EPS
- SBRA 0.60
- ICUI N/A
- Revenue
- SBRA $720,247,000.00
- ICUI $2,420,093,000.00
- Revenue This Year
- SBRA $5.91
- ICUI N/A
- Revenue Next Year
- SBRA $5.30
- ICUI N/A
- P/E Ratio
- SBRA $30.82
- ICUI N/A
- Revenue Growth
- SBRA 10.76
- ICUI 7.22
- 52 Week Low
- SBRA $15.49
- ICUI $117.92
- 52 Week High
- SBRA $20.03
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- SBRA 54.92
- ICUI 50.47
- Support Level
- SBRA $18.27
- ICUI $129.26
- Resistance Level
- SBRA $18.56
- ICUI $139.41
- Average True Range (ATR)
- SBRA 0.32
- ICUI 4.24
- MACD
- SBRA -0.02
- ICUI 0.53
- Stochastic Oscillator
- SBRA 55.43
- ICUI 59.68
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.